Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 466

1.

Microenvironmental Th9- and Th17- lymphocytes induce metastatic spreading in lung cancer.

Salazar Y, Zheng X, Brunn D, Raifer H, Picard FS, Zhang Y, Winter H, Günther S, Weigert A, Weigmann B, Dumoutier L, Renauld JC, Waisman A, Schmall A, Tufman A, Fink L, Brüne B, Bopp T, Grimminger F, Seeger W, Pullamsetti SS, Huber M, Savai R.

J Clin Invest. 2020 Mar 31. pii: 124037. doi: 10.1172/JCI124037. [Epub ahead of print]

2.

Macrophage and Tumor Cell Cross-Talk Is Fundamental for Lung Tumor Progression: We Need to Talk.

Sarode P, Schaefer MB, Grimminger F, Seeger W, Savai R.

Front Oncol. 2020 Mar 11;10:324. doi: 10.3389/fonc.2020.00324. eCollection 2020. Review.

3.

Amelioration of elastase-induced lung emphysema and reversal of pulmonary hypertension by pharmacological iNOS inhibition in mice.

Fysikopoulos A, Seimetz M, Hadzic S, Knoepp F, Wu CY, Malkmus K, Wilhelm J, Pichl A, Bednorz M, Tadele Roxlau E, Ghofrani HA, Sommer N, Gierhardt M, Schermuly RT, Seeger W, Grimminger F, Weissmann N, Kraut S.

Br J Pharmacol. 2020 Mar 22. doi: 10.1111/bph.15057. [Epub ahead of print]

PMID:
32201936
4.

FHL-1 is not involved in pressure overload-induced maladaptive right ventricular remodeling and dysfunction.

Veith C, Neghabian D, Luitel H, Wilhelm J, Egemnazarov B, Muntanjohl C, Fischer JH, Dahal BK, Schermuly RT, Ghofrani HA, Grimminger F, Fink L, Kwapiszewska G, Weissmann N, Sydykov A.

Basic Res Cardiol. 2020 Jan 24;115(2):17. doi: 10.1007/s00395-019-0767-5.

5.

Kinases as potential targets for treatment of pulmonary hypertension and right ventricular dysfunction.

Weiss A, Boehm M, Egemnazarov B, Grimminger F, Savai Pullamsetti S, Kwapiszewska G, Schermuly RT.

Br J Pharmacol. 2019 Nov 10. doi: 10.1111/bph.14919. [Epub ahead of print] Review.

PMID:
31709514
6.

Epithelial cell plasticity defines heterogeneity in lung cancer.

Sarode P, Mansouri S, Karger A, Schaefer MB, Grimminger F, Seeger W, Savai R.

Cell Signal. 2020 Jan;65:109463. doi: 10.1016/j.cellsig.2019.109463. Epub 2019 Nov 3.

PMID:
31693875
7.

Evaluation and Prognostic Relevance of Right Ventricular-Arterial Coupling in Pulmonary Hypertension.

Richter MJ, Peters D, Ghofrani HA, Naeije R, Roller F, Sommer N, Gall H, Grimminger F, Seeger W, Tello K.

Am J Respir Crit Care Med. 2020 Jan 1;201(1):116-119. doi: 10.1164/rccm.201906-1195LE. No abstract available.

PMID:
31539478
8.

Is PKM2 Phosphorylation a Prerequisite for Oligomer Disassembly in Pulmonary Arterial Hypertension?

Novoyatleva T, Rai N, Weissmann N, Grimminger F, Ghofrani HA, Seeger W, Gall H, Schermuly RT.

Am J Respir Crit Care Med. 2019 Dec 15;200(12):1550-1554. doi: 10.1164/rccm.201904-0782LE. No abstract available.

PMID:
31486671
9.

Reply to Bogaard et al.: Emphysema Is-at the Most-Only a Mild Phenotype in the Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension.

Kojonazarov B, Hadzic S, Ghofrani HA, Grimminger F, Seeger W, Weissmann N, Schermuly RT.

Am J Respir Crit Care Med. 2019 Dec 1;200(11):1450-1452. doi: 10.1164/rccm.201907-1367LE. No abstract available.

10.

Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension.

Weiss A, Neubauer MC, Yerabolu D, Kojonazarov B, Schlueter BC, Neubert L, Jonigk D, Baal N, Ruppert C, Dorfmuller P, Pullamsetti SS, Weissmann N, Ghofrani HA, Grimminger F, Seeger W, Schermuly RT.

Nat Commun. 2019 May 17;10(1):2204. doi: 10.1038/s41467-019-10135-x.

11.

A RASSF1A-HIF1α loop drives Warburg effect in cancer and pulmonary hypertension.

Dabral S, Muecke C, Valasarajan C, Schmoranzer M, Wietelmann A, Semenza GL, Meister M, Muley T, Seeger-Nukpezah T, Samakovlis C, Weissmann N, Grimminger F, Seeger W, Savai R, Pullamsetti SS.

Nat Commun. 2019 May 13;10(1):2130. doi: 10.1038/s41467-019-10044-z.

12.

Severe Emphysema in the SU5416/Hypoxia Rat Model of Pulmonary Hypertension.

Kojonazarov B, Hadzic S, Ghofrani HA, Grimminger F, Seeger W, Weissmann N, Schermuly RT.

Am J Respir Crit Care Med. 2019 Aug 15;200(4):515-518. doi: 10.1164/rccm.201902-0390LE. No abstract available.

PMID:
31034778
13.

Altered proteasome function in right ventricular hypertrophy.

Heitmeier T, Sydykov A, Lukas C, Vroom C, Korfei M, Petrovic A, Klingel K, Günther A, Eickelberg O, Weissmann N, Ghofrani HA, Seeger W, Grimminger F, Schermuly RT, Meiners S, Kosanovic D.

Cardiovasc Res. 2020 Feb 1;116(2):406-415. doi: 10.1093/cvr/cvz103.

PMID:
31020333
14.

Riociguat for treatment of pulmonary hypertension in COPD: a translational study.

Pichl A, Sommer N, Bednorz M, Seimetz M, Hadzic S, Kuhnert S, Kraut S, Roxlau ET, Kojonazarov B, Wilhelm J, Gredic M, Gall H, Tello K, Richter MJ, Pak O, Petrovic A, Hecker M, Schermuly RT, Grimminger F, Seeger W, Ghofrani HA, Weissmann N.

Eur Respir J. 2019 Jun 27;53(6). pii: 1802445. doi: 10.1183/13993003.02445-2018. Print 2019 Jun.

PMID:
30956210
15.

Evidence for the Fucoidan/P-Selectin Axis as a Therapeutic Target in Hypoxia-induced Pulmonary Hypertension.

Novoyatleva T, Kojonazarov B, Owczarek A, Veeroju S, Rai N, Henneke I, Böhm M, Grimminger F, Ghofrani HA, Seeger W, Weissmann N, Schermuly RT.

Am J Respir Crit Care Med. 2019 Jun 1;199(11):1407-1420. doi: 10.1164/rccm.201806-1170OC.

PMID:
30557519
16.

Evaluating Systolic and Diastolic Cardiac Function in Rodents Using Microscopic Computed Tomography.

Kojonazarov B, Belenkov A, Shinomiya S, Wilchelm J, Kampschulte M, Mizuno S, Ghofrani HA, Grimminger F, Weissmann N, Seeger W, Schermuly RT.

Circ Cardiovasc Imaging. 2018 Dec;11(12):e007653. doi: 10.1161/CIRCIMAGING.118.007653.

PMID:
30525986
17.

Long-term safety and outcome of intravenous treprostinil via an implanted pump in pulmonary hypertension.

Richter MJ, Harutyunova S, Bollmann T, Classen S, Gall H, Gerhardt Md F, Grimminger F, Grimminger J, Grünig E, Guth S, Halank M, Heine A, Hoeper MM, Klose H, Lange TJ, Meyer K, Neurohr C, Nickolaus K, Olsson KM, Opitz CF, Rosenkranz S, Seyfarth HJ, Warnke C, Wiedenroth C, Ghofrani HA, Ewert R.

J Heart Lung Transplant. 2018 Oct;37(10):1235-1244. doi: 10.1016/j.healun.2018.06.006. Epub 2018 Jun 21.

PMID:
30293617
18.

Targeting CREB-binding protein overrides LPS induced radioresistance in non-small cell lung cancer cell lines.

Gökyildirim MY, Grandel U, Hattar K, Dahlem G, Schuetz E, Leinberger FH, Eberle F, Sibelius U, Grimminger F, Seeger W, Engenhart-Cabillic R, Dikomey E, Subtil FSB.

Oncotarget. 2018 Jun 22;9(48):28976-28988. doi: 10.18632/oncotarget.25665. eCollection 2018 Jun 22.

19.

Hypoxic pulmonary vasoconstriction in isolated mouse pulmonary arterial vessels.

Strielkov I, Krause NC, Sommer N, Schermuly RT, Ghofrani HA, Grimminger F, Gudermann T, Dietrich A, Weissmann N.

Exp Physiol. 2018 Sep;103(9):1185-1191. doi: 10.1113/EP087117. Epub 2018 Jul 6.

PMID:
29917290
20.

Nintedanib in Severe Pulmonary Arterial Hypertension.

Richter MJ, Ewert J, Grimminger F, Ghofrani HA, Kojonazarov B, Petrovic A, Seeger W, Schermuly RT, Tello K, Gall H.

Am J Respir Crit Care Med. 2018 Sep 15;198(6):808-810. doi: 10.1164/rccm.201801-0195LE. No abstract available.

PMID:
29763335
21.

Combined human papillomavirus typing and TP53 mutation analysis in distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma.

Daher T, Tur MK, Brobeil A, Etschmann B, Witte B, Engenhart-Cabillic R, Krombach G, Blau W, Grimminger F, Seeger W, Klussmann JP, Bräuninger A, Gattenlöhner S.

Head Neck. 2018 Jun;40(6):1109-1119. doi: 10.1002/hed.25041. Epub 2018 Mar 9.

PMID:
29522268
22.

Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension.

Boehm M, Arnold N, Braithwaite A, Pickworth J, Lu C, Novoyatleva T, Kiely DG, Grimminger F, Ghofrani HA, Weissmann N, Seeger W, Lawrie A, Schermuly RT, Kojonazarov B.

BMC Pulm Med. 2018 Mar 2;18(1):41. doi: 10.1186/s12890-018-0604-x.

23.

FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis.

Al-Tamari HM, Dabral S, Schmall A, Sarvari P, Ruppert C, Paik J, DePinho RA, Grimminger F, Eickelberg O, Guenther A, Seeger W, Savai R, Pullamsetti SS.

EMBO Mol Med. 2018 Feb;10(2):276-293. doi: 10.15252/emmm.201606261.

24.

Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk.

Pullamsetti SS, Kojonazarov B, Storn S, Gall H, Salazar Y, Wolf J, Weigert A, El-Nikhely N, Ghofrani HA, Krombach GA, Fink L, Gattenlöhner S, Rapp UR, Schermuly RT, Grimminger F, Seeger W, Savai R.

Sci Transl Med. 2017 Nov 15;9(416). pii: eaai9048. doi: 10.1126/scitranslmed.aai9048.

PMID:
29141888
25.

ASK1 Inhibition Halts Disease Progression in Preclinical Models of Pulmonary Arterial Hypertension.

Budas GR, Boehm M, Kojonazarov B, Viswanathan G, Tian X, Veeroju S, Novoyatleva T, Grimminger F, Hinojosa-Kirschenbaum F, Ghofrani HA, Weissmann N, Seeger W, Liles JT, Schermuly RT.

Am J Respir Crit Care Med. 2018 Feb 1;197(3):373-385. doi: 10.1164/rccm.201703-0502OC.

PMID:
28910144
26.

[Update pulmonary arterial hypertension : Definitions, diagnosis, therapy].

Sommer N, Richter MJ, Tello K, Grimminger F, Seeger W, Ghofrani HA, Gall H.

Internist (Berl). 2017 Sep;58(9):937-957. doi: 10.1007/s00108-017-0301-5. German.

PMID:
28819824
27.

p38 MAPK Inhibition Improves Heart Function in Pressure-Loaded Right Ventricular Hypertrophy.

Kojonazarov B, Novoyatleva T, Boehm M, Happe C, Sibinska Z, Tian X, Sajjad A, Luitel H, Kriechling P, Posern G, Evans SM, Grimminger F, Ghofrani HA, Weissmann N, Bogaard HJ, Seeger W, Schermuly RT.

Am J Respir Cell Mol Biol. 2017 Nov;57(5):603-614. doi: 10.1165/rcmb.2016-0374OC.

PMID:
28657795
28.

Mitochondrial Complex IV Subunit 4 Isoform 2 Is Essential for Acute Pulmonary Oxygen Sensing.

Sommer N, Hüttemann M, Pak O, Scheibe S, Knoepp F, Sinkler C, Malczyk M, Gierhardt M, Esfandiary A, Kraut S, Jonas F, Veith C, Aras S, Sydykov A, Alebrahimdehkordi N, Giehl K, Hecker M, Brandes RP, Seeger W, Grimminger F, Ghofrani HA, Schermuly RT, Grossman LI, Weissmann N.

Circ Res. 2017 Aug 4;121(4):424-438. doi: 10.1161/CIRCRESAHA.116.310482. Epub 2017 Jun 15.

29.

Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study.

Halank M, Hoeper MM, Ghofrani HA, Meyer FJ, Stähler G, Behr J, Ewert R, Fletcher M, Colorado P, Nikkho S, Grimminger F.

Respir Med. 2017 Jul;128:50-56. doi: 10.1016/j.rmed.2017.05.008. Epub 2017 May 16.

30.

Chronic intratracheal application of the soluble guanylyl cyclase stimulator BAY 41-8543 ameliorates experimental pulmonary hypertension.

Amirjanians M, Egemnazarov B, Sydykov A, Kojonazarov B, Brandes R, Luitel H, Pradhan K, Stasch JP, Redlich G, Weissmann N, Grimminger F, Seeger W, Ghofrani H, Schermuly R.

Oncotarget. 2017 May 2;8(18):29613-29624. doi: 10.18632/oncotarget.16769.

31.

Pressure overload leads to an increased accumulation and activity of mast cells in the right ventricle.

Luitel H, Sydykov A, Schymura Y, Mamazhakypov A, Janssen W, Pradhan K, Wietelmann A, Kosanovic D, Dahal BK, Weissmann N, Seeger W, Grimminger F, Ghofrani HA, Schermuly RT.

Physiol Rep. 2017 Mar;5(6). pii: e13146. doi: 10.14814/phy2.13146.

32.

Lipoteichoic acids from Staphylococcus aureus stimulate proliferation of human non-small-cell lung cancer cells in vitro.

Hattar K, Reinert CP, Sibelius U, Gökyildirim MY, Subtil FSB, Wilhelm J, Eul B, Dahlem G, Grimminger F, Seeger W, Grandel U.

Cancer Immunol Immunother. 2017 Jun;66(6):799-809. doi: 10.1007/s00262-017-1980-4. Epub 2017 Mar 17.

33.

The Giessen Pulmonary Hypertension Registry: Survival in pulmonary hypertension subgroups.

Gall H, Felix JF, Schneck FK, Milger K, Sommer N, Voswinckel R, Franco OH, Hofman A, Schermuly RT, Weissmann N, Grimminger F, Seeger W, Ghofrani HA.

J Heart Lung Transplant. 2017 Sep;36(9):957-967. doi: 10.1016/j.healun.2017.02.016. Epub 2017 Feb 17.

34.

Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study.

Galiè N, Grimminger F, Grünig E, Hoeper MM, Humbert M, Jing ZC, Keogh AM, Langleben D, Rubin LJ, Fritsch A, Davie N, Ghofrani HA.

J Heart Lung Transplant. 2017 May;36(5):509-519. doi: 10.1016/j.healun.2016.12.012. Epub 2016 Dec 24.

35.

Amplified canonical transforming growth factor-β signalling via heat shock protein 90 in pulmonary fibrosis.

Sibinska Z, Tian X, Korfei M, Kojonazarov B, Kolb JS, Klepetko W, Kosanovic D, Wygrecka M, Ghofrani HA, Weissmann N, Grimminger F, Seeger W, Guenther A, Schermuly RT.

Eur Respir J. 2017 Feb 23;49(2). pii: 1501941. doi: 10.1183/13993003.01941-2015. Print 2017 Feb.

36.

Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension.

Kim NH, D'Armini AM, Grimminger F, Grünig E, Hoeper MM, Jansa P, Mayer E, Neurohr C, Simonneau G, Torbicki A, Wang C, Fritsch A, Davie N, Ghofrani HA.

Heart. 2017 Apr;103(8):599-606. doi: 10.1136/heartjnl-2016-309621. Epub 2016 Dec 23.

37.

Maintained right ventricular pressure overload induces ventricular-arterial decoupling in mice.

Boehm M, Lawrie A, Wilhelm J, Ghofrani HA, Grimminger F, Weissmann N, Seeger W, Schermuly RT, Kojonazarov B.

Exp Physiol. 2017 Feb 1;102(2):180-189. doi: 10.1113/EP085963.

38.

Procedural safety of a fully implantable intravenous prostanoid pump for pulmonary hypertension.

Richter MJ, Ewert R, Warnke C, Gall H, Classen S, Grimminger F, Mayer E, Seeger W, Ghofrani HA.

Clin Res Cardiol. 2017 Mar;106(3):174-182. doi: 10.1007/s00392-016-1037-2. Epub 2016 Sep 26.

PMID:
27670656
39.

Biomarkers of tissue remodeling predict survival in patients with pulmonary hypertension.

Tiede SL, Wassenberg M, Christ K, Schermuly RT, Seeger W, Grimminger F, Ghofrani HA, Gall H.

Int J Cardiol. 2016 Nov 15;223:821-826. doi: 10.1016/j.ijcard.2016.08.240. Epub 2016 Aug 13.

PMID:
27575785
40.

Notch1 signalling regulates endothelial proliferation and apoptosis in pulmonary arterial hypertension.

Dabral S, Tian X, Kojonazarov B, Savai R, Ghofrani HA, Weissmann N, Florio M, Sun J, Jonigk D, Maegel L, Grimminger F, Seeger W, Savai Pullamsetti S, Schermuly RT.

Eur Respir J. 2016 Oct;48(4):1137-1149. doi: 10.1183/13993003.00773-2015. Epub 2016 Jul 28.

41.

Selexipag for the treatment of pulmonary arterial hypertension.

Richter MJ, Gall H, Grimminger J, Grimminger F, Ghofrani HA.

Expert Opin Pharmacother. 2016 Sep;17(13):1825-34. doi: 10.1080/14656566.2016.1215429. Epub 2016 Aug 2. Review.

PMID:
27467883
42.

Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.

Humbert M, Coghlan JG, Ghofrani HA, Grimminger F, He JG, Riemekasten G, Vizza CD, Boeckenhoff A, Meier C, de Oliveira Pena J, Denton CP.

Ann Rheum Dis. 2017 Feb;76(2):422-426. doi: 10.1136/annrheumdis-2015-209087. Epub 2016 Jul 25.

43.

COPD-associated pulmonary hypertension: clinical implications and current methods for treatment.

Grimminger J, Ghofrani HA, Weissmann N, Klose H, Grimminger F.

Expert Rev Respir Med. 2016 Jul;10(7):755-66. doi: 10.1080/17476348.2016.1190275. Epub 2016 Jun 7. Review.

PMID:
27212458
44.

Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.

Pradhan K, Sydykov A, Tian X, Mamazhakypov A, Neupane B, Luitel H, Weissmann N, Seeger W, Grimminger F, Kretschmer A, Stasch JP, Ghofrani HA, Schermuly RT.

Int J Cardiol. 2016 Aug 1;216:85-91. doi: 10.1016/j.ijcard.2016.04.098. Epub 2016 Apr 16.

PMID:
27140341
45.

Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.

Ghofrani HA, Grimminger F, Grünig E, Huang Y, Jansa P, Jing ZC, Kilpatrick D, Langleben D, Rosenkranz S, Menezes F, Fritsch A, Nikkho S, Humbert M.

Lancet Respir Med. 2016 May;4(5):361-71. doi: 10.1016/S2213-2600(16)30019-4. Epub 2016 Apr 8.

PMID:
27067479
46.

Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial.

Simonneau G, D'Armini AM, Ghofrani HA, Grimminger F, Jansa P, Kim NH, Mayer E, Pulido T, Wang C, Colorado P, Fritsch A, Meier C, Nikkho S, Hoeper MM.

Lancet Respir Med. 2016 May;4(5):372-80. doi: 10.1016/S2213-2600(16)30022-4. Epub 2016 Apr 8.

PMID:
27067478
47.

The Clinical Significance of HbA1c in Operable Chronic Thromboembolic Pulmonary Hypertension.

Richter MJ, Milger K, Haase S, Sommer N, Tello K, Seeger W, Mayer E, Wiedenroth CB, Grimminger F, George W, Ghofrani HA, Guth S, Gall H.

PLoS One. 2016 Mar 31;11(3):e0152580. doi: 10.1371/journal.pone.0152580. eCollection 2016.

48.

Survival with sildenafil and inhaled iloprost in a cohort with pulmonary hypertension: an observational study.

Gall H, Sommer N, Milger K, Richter MJ, Voswinckel R, Bandorski D, Seeger W, Grimminger F, Ghofrani HA.

BMC Pulm Med. 2016 Jan 12;16:5. doi: 10.1186/s12890-015-0164-2.

49.

The prognostic relevance of oxygen uptake in inoperable chronic thromboembolic pulmonary hypertension.

Richter MJ, Pader P, Gall H, Reichenberger F, Seeger W, Mayer E, Guth S, Kramm T, Grimminger F, Ghofrani HA, Voswinckel R.

Clin Respir J. 2017 Nov;11(6):682-690. doi: 10.1111/crj.12399. Epub 2015 Nov 3.

PMID:
26470843
50.

Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma.

Banat GA, Tretyn A, Pullamsetti SS, Wilhelm J, Weigert A, Olesch C, Ebel K, Stiewe T, Grimminger F, Seeger W, Fink L, Savai R.

PLoS One. 2015 Sep 28;10(9):e0139073. doi: 10.1371/journal.pone.0139073. eCollection 2015.

Supplemental Content

Loading ...
Support Center